InterMune Inc. (ITMN)
-NasdaqGS 9.99 
0.31(3.01%) 18 May 04:00 SGT|After Hours
:
9.99 0.00 (0.00%) 18 May 04:56 SGT
| Prev Close: | 10.30 |
|---|
| Open: | 10.41 |
|---|
| Bid: | 7.87 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.29 |
|---|
| Beta: | 4.28 |
|---|
| Next Earnings Date: | 24-Jul-13 |
|---|
| Day's Range: | 9.94 - 10.54 |
|---|
| 52wk Range: | 7.21 - 12.77 |
|---|
| Volume: | 1,541,438 |
|---|
| Avg Vol (3m): | 1,335,400 |
|---|
| Market Cap: | 816.02M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.34 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- INTERMUNE INC FinancialsEDGAR Online Financials(Sun, 12 May)
- Kyrgyzstan Decries Dismissal of U.S. Case Against Bakiyevat Bloomberg(Sat, 11 May)
- U.S. Case Ends Against Ex-Kyrgyz Leader Bakiyev’s Sonat Bloomberg(Fri, 10 May)
- After AbbVie's Humira: What Next?at Seeking Alpha(Tue, 7 May)
- INTERMUNE INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Mon, 6 May)
- 2 Biotechs To Avoid, 1 To Buyat Motley Fool(Sat, 4 May)
- Positive News in the Oncology Space Regarding Myeloma and Melanoma Drugs: Expert Analyst Boris Peaker Discusses Recent Successes for Biotechnology CompaniesWall Street Transcript(Wed, 1 May)
- UPDATE 1-Europe's regulator digs in for drug data fightat Reuters(Tue, 30 Apr)
- Court stops EU regulator releasing drug company dataat Reuters(Tue, 30 Apr)
- InterMune loss widens in first quarter on costsAP(Thu, 25 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 26.44 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.78 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.70 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | 0.21 |
|---|
Business Summary
InterMune, Inc., a biotechnology company, engages in the research, development, and commercialization of therapies in pulmonology and orphan fibrotic diseases.
View More